-transparent.png){kind=logo}
Sixty-nine patients with acute nonlymphocytic leukemia in first remission received total-body irradiation and chemotherapy followed by allogeneic bone marrow transplantation from histocompatible sibling donors. Patient age was between 1 and 41 years: 20 patients 1-19 years (group 1); 27 patients 20-29 years (group 2); and 22 patients 30-41 years (group 3). Two pretransplant radiochemotherapy regimens were employed: The first 45 patients received total-body irradiation (in a single dose) with cytosine arabinoside and cyclophosphamide; the next 24 patients received total-body irradiation (in a fractionated schedule) with cyclophosphamide alone. For all patients, actuarial disease-free survival is 51% (37 of 69 patients are alive and in continuous remission between 5 months and 9.3 years, median 3.7 years). For group 1 actuarial survival is 56%, group 2 48%, and group 3 48%. When analyzed for pretransplant factors that might predict disease-free survival after bone marrow transplantation neither patient age, white cell count at the time of diagnosis, FAB leukemic subtype, length of time before achieving remission, nor length of time between remission and bone marrow transplantation were established as prognostic.
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
September 1979,
The New England journal of medicine,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
May 1985,
Blood,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
August 1985,
Blood,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
January 1981,
Medical and pediatric oncology,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
June 1984,
American journal of clinical oncology,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
October 1991,
Blood,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
July 1982,
Cancer treatment reports,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
January 1984,
Seminars in hematology,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
April 1997,
Blood,
S J Forman, and
R A Krance, and
M R O'Donnell, and
A P Nademanee, and
D S Snyder, and
J L Fahey, and
G M Schmidt, and
J A Zaia, and
J A Lipsett, and
D O Findley
October 1995,
Bone marrow transplantation,
